SCHEMBL533144

SCHEMBL533144

CCCCCCC(Nc1cccc(C(N)(Cc2ccc(-c3nccs3)cc2)S(=O)(=O)c2ccccn2)n1)C(=O)O

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.34
PTGER2 P43116 7/20 0.34
MMP9 P14780 2/20 0.33
MMP1 P03956 1/20 0.33
MMP3 P08254 1/20 0.33
ADAM17 P78536 1/20 0.33
CAPN1 P07384 1/20 0.33
PTGES O14684 2/20 0.32
LOXL2 Q9Y4K0 1/20 0.32
ALOX5 P09917 1/20 0.32
MMP2 P08253 1/20 0.32
MMP8 P22894 1/20 0.32
MMP12 P39900 1/20 0.32
MMP14 P50281 1/20 0.32
HSPA5 P11021 1/20 0.32
AGTR2 P50052 1/20 0.32
ALOX5AP P20292 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12077259 1.00 KAT6A (0.34) KAT6APTGER2MMP9MMP1MMP3
Hydrochloric Acid SCHEMBL12077089 0.99 PTGER2 (0.35) KAT6APTGER2MMP9MMP1MMP3
SCHEMBL12077060 0.93 KAT6A (0.34) KAT6APTGER2LOXL2
SCHEMBL12077126 0.93 KAT6A (0.34) KAT6APTGER2LOXL2
SCHEMBL533210 0.91 KAT6A (0.37) KAT6APTGER2LOXL2ALOX5AP
SCHEMBL12077394 0.86 PTGER2 (0.35) KAT6APTGER2LOXL2
SCHEMBL10316594 0.86 KAT6A (0.33) KAT6APTGER2LOXL2ALOX5AP
SCHEMBL10317066 0.85 KAT6A (0.34) KAT6APTGER2LOXL2ALOX5AP
SCHEMBL533228 0.85 MMP2 (0.38) KAT6APTGER2MMP9MMP3LOXL2
SCHEMBL12076991 0.84 CASR (0.41) KAT6AMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2415763-B1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA UBE INDUSTRIES (JP) 2016-01-27 EP claimed
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA UBE INDUSTRIES, LTD. (JP) 2012-07-26 US claimed
EP-2415763-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA Ube Industries, Ltd. (JP) 2012-02-08 EP claimed
US-8648097-B2 Pyridylaminoacetic acid compound UBE INDUSTRIES, LTD. (JP) 2014-02-11 US disclosed
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA UBE INDUSTRIES, LTD. (JP) 2012-07-26 US disclosed
EP-2415763-A1 PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA Ube Industries, Ltd. (JP) 2012-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190852-A1 MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA F12, C1S, AKR1C3 KAT6A 1992/4885PTGER2 24/4885MMP9 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.